Fig. 1

Identification of Oncostatin M as a potent inducer of muscle stem cell engraftment. a Schematic of combined in vitro/in vivo bioluminescence imaging (BLI) screening strategy. b Schematic of deconvolution for positive protein pools. Pools of 22 proteins scoring for engraftment in the initial round of screening were iteratively deconvolved into pools of 4 proteins, and then individual proteins. c Results of multiplexed in vitro/in vivo protein screening. Black, results of in vitro BLI; red, results of in vivo BLI. Ctl: control buffer; SB: SB202190; FGF: recombinant human basic fibroblast growth factor. Symbols below the axis mark pools containing OSM (star), and all other hits (circle; includes FGF, TNFR, and incompletely deconvolved pools). d Representative BLI results following treatment of 800 FACS-sorted MuSC with either FGF or Oncostatin M (OSM; 100 ng/mL) for 6 days in vitro, followed by intramuscular transplantation (3 8-12 week old animals each) and in vivo BLI measurement 6 days (open circles) or 2 weeks (shaded circles) after transplant. e Schematic (left) demonstrating transplantation of 250 counted progeny of CD11b⁻Sca1⁻CD31⁻CD45⁻CD34⁺αα7 integrin⁺ stem cells following long-term 2 week culture with OSM control conditions (FGF). Serial BLI following transplantation of counted cells (right). Each point indicates an individual hindlimb that received a 250 cell transplant, n = 10 per condition. BLI is shown for weeks 1 (white) and 2 (light gray) pre-CTX, and weeks 1 (dark gray) and 10 (red) post-CTX. Double asterisks indicate p < 0.01 in comparison with control condition at the same timepoint